M. Stepanova

发表

Effects of Temperature on the p53-DNA Binding Interactions and Their Dynamical Behavior: Comparing the Wild Type to the R248Q Mutant

Jack Tuszynski, Khaled Barakat, J. Tuszynski, 2011, PloS one.

Combining molecular dynamics simulations and experimental analyses in protein misfolding.

M. Stepanova, H. Wille, L. Dorosh, 2019, Advances in protein chemistry and structural biology.

Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

M. Stepanova, Z. Younossi, M. Afendy, 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Potential regulatory SNPs in promoters of human genes: a systematic approach.

Tatiana Tiazhelova, Ancha Baranova, A. Baranova, 2006, Molecular and cellular probes.

M. Stepanova, Z. Younossi, M. Fernández, 2020, Annals of hepatology.

Epidemiology of chronic liver diseases in the USA in the past three decades

M. Stepanova, L. Henry, Z. Younossi, 2019, Gut.

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

Robert Blissett, Rachel Beckerman, Andrei Racila, 2016, Hepatology.

Exploring the essential collective dynamics of interacting proteins: Application to prion protein dimers

Bilkiss B. Issack, M. Stepanova, M. Berjanskii, 2012, Proteins.

Comparative analysis of essential collective dynamics and NMR-derived flexibility profiles in evolutionarily diverse prion proteins

D. Wishart, M. Stepanova, M. Berjanskii, 2011, Prion.

Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C

M. Stepanova, Z. Younossi, C. Venkatesan, 2013, Alimentary pharmacology & therapeutics.

A novel Gerstmann-Sträussler-Scheinker disease mutation defines a precursor for amyloidogenic 8 kDa PrP fragments and reveals N-terminal structural changes shared by other GSS alleles

B. Sykes, G. Jansen, D. Westaway, 2018, PLoS pathogens.

Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels

L. Gerber, M. Stepanova, Z. Younossi, 2015, Journal of viral hepatitis.

Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.

M. Stepanova, S. Zeuzem, L. Henry, 2016, Journal of hepatology.

Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.

M. Stepanova, Z. Younossi, 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Probing oligomerization of amyloid beta peptide in silico.

M. Stepanova, L. Dorosh, 2016, Molecular bioSystems.

A Novel method for estimating right atrial pressure with point-of-care ultrasound (POCUS)

M. Stepanova, L. Istrail, J. Kiernan, 2022, medRxiv.

Inpatient Economic and Mortality Assessment for Liver Transplantation: A Nationwide Study of the United States Data From 2005 to 2009

S. Saab, M. Stepanova, Z. Younossi, 2014, Transplantation.

A Profile HMM for Recognition of Hormone Response Elements

Feng Lin, Maria Stepanova, Valerie C.-L. Lin, 2006, PRIB.

A Two-Phase ANN Method for Genome-Wide Detection of Hormone Response Elements

Feng Lin, Maria Stepanova, Valerie C.-L. Lin, 2007, PRIB.

Establishing a statistic model for recognition of steroid hormone response elements

Feng Lin, Maria Stepanova, Valerie C.-L. Lin, 2006, Comput. Biol. Chem..

Impact of healthcare reform on the payer mix among young adult emergency department utilizers across the United States (2005–2015)

L. Gerber, M. Stepanova, Z. Younossi, 2018, Medicine.

Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis

S. Saab, M. Stepanova, L. Henry, 2015, BMC Gastroenterology.

Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States

F. Negro, M. Stepanova, Z. Younossi, 2012, Medicine.

Anti‐adipocyte antibody response in patients with non‐alcoholic fatty liver disease

Z. Goodman, M. Stepanova, Z. Younossi, 2015, Journal of gastroenterology and hepatology.

The effect of interferon‐free regimens on health‐related quality of life in East Asian patients with chronic hepatitis C

J. Kao, M. Yuen, Ching-lung Lai, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Age-independent rise of inflammatory scores may contribute to accelerated aging in multi-morbidity

A. Baranova, M. Stepanova, A. Birerdinc, 2015, Oncotarget.

New mutations in the Notch3 gene in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL)

M. Stepanova, S. Illarioshkin, M. Zakharova, 2015, Journal of the Neurological Sciences.

Patients' preferences and health utility assessment with SF‐6D and EQ‐5D in patients with chronic hepatitis C treated with sofosbuvir regimens

M. Stepanova, Z. Younossi, S. Hunt, 2014, Alimentary pharmacology & therapeutics.

Patient‐reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir‐containing regimens

M. Stepanova, D. Nelson, Z. Younossi, 2014, Hepatology.

Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH‐C)

M. Stepanova, Z. Younossi, A. Birerdinc, 2012, Journal of viral hepatitis.

Systematic review with meta‐analysis: extrahepatic manifestations in chronic hepatitis C virus‐infected patients in East Asia

M. Stepanova, M. Mizokami, Y. Eguchi, 2019, Alimentary pharmacology & therapeutics.

Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)

A. Baranova, M. Stepanova, Z. Younossi, 2012, Brain and behavior.

Insurance status and treatment candidacy of hepatitis C patients: Analysis of population‐based data from the United States

H. El‐Serag, M. Stepanova, Z. Younossi, 2011, Hepatology.

S. Hunt, P. Rosenthal, M. Stepanova, 2018, Journal of pediatric gastroenterology and nutrition.

Long‐term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry

M. Stepanova, Z. Younossi, C. Venkatesan, 2016, Clinical transplantation.

Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease

M. Stepanova, L. Henry, Z. Younossi, 2021, JAMA network open.

Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage

M. Stepanova, Z. Younossi, 2015, Digestive Diseases and Sciences.

Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin

M. Stepanova, L. Henry, Z. Younossi, 2018, Journal of viral hepatitis.

African Americans Are Less Likely to Have Clearance of Hepatitis C Virus Infection: The Findings from Recent U.S. Population Data

M. Stepanova, Z. Younossi, M. Afendy, 2012, Journal of clinical gastroenterology.

Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials

P. Marcellin, M. Stepanova, K. Kowdley, 2015, Hepatology.

Vietnamese community screening for hepatitis B virus and hepatitis C virus

M. Stepanova, M. Srishord, J. Kallman, 2011, Journal of viral hepatitis.

Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

M. Stepanova, L. Henry, D. Nelson, 2014, Journal of hepatology.

The impact of chronic hepatitis C on resource utilisation and in‐patient mortality for Medicare beneficiaries between 2005 and 2010

M. Stepanova, L. Henry, Z. Younossi, 2013, Alimentary pharmacology & therapeutics.

Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health‐related quality of life in East Asian patients with hepatitis C virus infection

J. Kao, Ching-lung Lai, H. Chan, 2018, Journal of viral hepatitis.

Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH‐C) patients: an economic model from five European countries

M. Buti, M. Stepanova, S. Mauss, 2016, Journal of viral hepatitis.

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir

M. Stepanova, M. Mizokami, M. Omata, 2016, Medicine.

Sofosbuvir and ledipasvir improve patient‐reported outcomes in patients co‐infected with hepatitis C and human immunodeficiency virus

M. Stepanova, L. Henry, Z. Younossi, 2016, Journal of viral hepatitis.

Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study

S. Hunt, M. Stepanova, Z. Younossi, 2016, BMC Gastroenterology.

The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study

M. Stepanova, S. Pol, M. Carrieri, 2016, Liver international : official journal of the International Association for the Study of the Liver.

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)

L. Gerber, M. Stepanova, Z. Younossi, 2016, Medicine.

Patient‐Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon‐ and Ribavirin‐Free Regimens

M. Stepanova, L. Henry, Z. Younossi, 2016, Journal of the American Geriatrics Society.

An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

M. Stepanova, L. Henry, Z. Younossi, 2016, The American Journal of Gastroenterology.

Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.

A. Mangia, M. Stepanova, L. Henry, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C.

M. Stepanova, L. Henry, Z. Younossi, 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.

P. Marcellin, M. Stepanova, K. Kowdley, 2015, Journal of hepatology.

Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States

M. Stepanova, Z. Younossi, R. Beckerman, 2015, Hepatology.

A meta‐analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection

M. Stepanova, L. Henry, A. Adeyemi, 2015, Journal of viral hepatitis.

Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.

F. Negro, M. Stepanova, Z. Younossi, 2016, Journal of hepatology.

Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.

O. Weiland, M. Stepanova, S. Zeuzem, 2014, Journal of hepatology.

Caffeine is protective in patients with non‐alcoholic fatty liver disease

M. Stepanova, Z. Younossi, A. Birerdinc, 2012, Alimentary pharmacology & therapeutics.

Cytokine balance is restored as patient‐reported outcomes improve in patients recovering from chronic hepatitis C

L. Gerber, M. Stepanova, Z. Younossi, 2019, Liver international : official journal of the International Association for the Study of the Liver.

Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients

M. Stepanova, Z. Younossi, P. Burra, 2022, Hepatology communications.

Reversible formation of nanodomains in monolayers of DPPC studied by kinetic modeling.

M. Stepanova, 2009, Biophysical journal.

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)

M. Stepanova, Z. Younossi, P. Golabi, 2018, BMJ open gastroenterology.

Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.

Z. Goodman, M. Stepanova, Z. Younossi, 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

ORIGINAL ARTICLES—LIVER, PANCREAS, AND BILIARY TRACT Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Z. Goodman, M. Stepanova, Z. Younossi, 2009 .

A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)

A. Baranova, Z. Goodman, M. Stepanova, 2008, Obesity surgery.

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Z. Goodman, M. Stepanova, K. Kowdley, 2021, Hepatology communications.

Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes

V. Wong, Z. Goodman, M. Stepanova, 2020, Hepatology communications.

Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.

M. Stepanova, A. Sanyal, Z. Younossi, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH).

V. Wong, M. Stepanova, M. Trauner, 2020, Gastroenterology.

Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.

M. Stepanova, Z. Younossi, A. Racila, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease

H. Makhlouf, Z. Goodman, M. Stepanova, 2017, Hepatology communications.

A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.

M. Buti, M. Zheng, M. Stepanova, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.

Z. Goodman, M. Stepanova, J. Bosch, 2018, Journal of hepatology.

Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in the United States.

M. Stepanova, L. Henry, Z. Younossi, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.

V. Wong, V. de Lédinghen, M. Stepanova, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Statin use is not associated with liver related mortality.

M. Stepanova, Z. Younossi, Z. Younoszai, 2014, Annals of hepatology.

Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C.

M. Stepanova, Z. Younossi, Yun Fang, 2011, Psychosomatics.

Case Report: Multiple Causes of Cardiac Death After the First Infusion of Atezolizumab: Histopathological and Immunohistochemical Findings

M. Stepanova, O. Moiseeva, E. Kushnareva, 2022, Frontiers in Immunology.

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin

A. Baranova, M. Stepanova, Z. Younossi, 2012, Journal of Translational Medicine.

Long‐term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry

R. Wong, S. Saab, M. Stepanova, 2016, Alimentary pharmacology & therapeutics.

C9ORF72 hexanucleotide repeat expansion in ALS patients from the Central European Russia population

M. Stepanova, V. Skvortsova, V. Buchman, 2015, Neurobiology of Aging.

Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices

M. Stepanova, Z. Younossi, M. Afendy, 2021, Clinical and translational gastroenterology.

Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS)

Z. Goodman, M. Stepanova, Z. Younossi, 2011, Scandinavian journal of gastroenterology.

Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis

R. Epstein, M. Stepanova, Z. Younossi, 2019, Journal of clinical gastroenterology.

In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009.

M. Stepanova, Z. Younossi, C. Venkatesan, 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Trends in Outpatient Resource Utilizations and Outcomes for Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease

M. Stepanova, L. Henry, Z. Younossi, 2015, Journal of clinical gastroenterology.

Association of Obestatin, Ghrelin, and Inflammatory Cytokines in Obese Patients with Non-alcoholic Fatty Liver Disease

A. Baranova, Z. Goodman, M. Stepanova, 2011, Obesity surgery.

Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis

Z. Goodman, M. Stepanova, G. Bratthauer, 2019, BMC Gastroenterology.

Reply.

M. Stepanova, Z. Younossi, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Outcomes of patients with non-alcoholic fatty liver disease

M. Stepanova, Z. Younossi, J. Ong, 2009 .

Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.

S. Hunt, M. Stepanova, Z. Younossi, 2016, The lancet. Gastroenterology & hepatology.

The Authors' reply

M. Stepanova, Z. Younossi, 2011, Gut.

Molecular mechanisms in the selective basal activation of pyrabactin receptor 1: Comparative analysis of mutants

M. Stepanova, L. Dorosh, M. Loewen, 2014, FEBS open bio.

Impairment of patient‐reported outcomes among patients with non‐alcoholic fatty liver disease: a registry‐based study

M. Stepanova, Z. Younossi, Y. Yılmaz, 2022, Alimentary pharmacology & therapeutics.

329 THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR)

S. Hamid, M. Stepanova, Y. Eguchi, 2020 .

Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV).

E. Petricoin, L. Liotta, A. Baranova, 2011, Journal of proteome research.

Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor

M. Stepanova, Z. Younossi, A. Racila, 2016, BMC Gastroenterology.

Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient‐Reported Outcomes

M. Stepanova, H. Janssen, Z. Younossi, 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study.

R. Jalan, D. Valla, M. Stepanova, 2017, Journal of hepatology.

Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology

M. Stepanova, H. Wille, L. Dorosh, 2022, Bioactive materials.

The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19

M. Stepanova, L. Henry, Z. Younossi, 2022, BMC Infectious Diseases.

Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience

L. Gerber, M. Stepanova, L. Henry, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.

M. Stepanova, Z. Younossi, C. Orkin, 2015, The Journal of infectious diseases.

Self-Consistent Field Modeling of Three-Dimensional Morphologies of Branched Lipid Surfactant at Air-Water Interface

M. Stepanova, A. Kovalenko, K. P. Santo, 2010 .

Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

V. Wong, F. Negro, M. Stepanova, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Non‐alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population‐based study

L. Gerber, M. Stepanova, Z. Younossi, 2012, Alimentary pharmacology & therapeutics.

Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States.

M. Stepanova, Z. Younossi, 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Clinical predictors of fibrosis in patients with chronic liver disease

Rajiv Gupta, M. Stepanova, Z. Younossi, 2010, Alimentary pharmacology & therapeutics.

Gene expression profile associated with superimposed non‐alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C

A. Baranova, M. Stepanova, Z. Younossi, 2009, Liver international : official journal of the International Association for the Study of the Liver.

Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon‐alfa and ribavirin

A. Baranova, Sheng-Yung P. Chang, M. Stepanova, 2009, Hepatology.

Development and validation of a hepatitis B‐specific health‐related quality‐of‐life instrument: CLDQ‐HBV

M. Stepanova, Z. Younossi, A. Racila, 2020, Journal of viral hepatitis.

Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population

M. Stepanova, Z. Younossi, 2011, Hepatology.

Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C

M. Stepanova, Z. Younossi, M. Afendy, 2013, Journal of viral hepatitis.

Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units

M. Stepanova, K. Brown, Z. Younossi, 2019, Journal of Viral Hepatitis.

Patient‐reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication

M. Stepanova, H. Janssen, Z. Younossi, 2019, Liver international : official journal of the International Association for the Study of the Liver.

Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir – stating the obvious? Authors' reply

M. Stepanova, Z. Younossi, 2014, Alimentary pharmacology & therapeutics.

The impact of type 2 diabetes and obesity on the long‐term outcomes of more than 85 000 liver transplant recipients in the US

S. Saab, M. Stepanova, L. Henry, 2014, Alimentary pharmacology & therapeutics.

Association of Components of Metabolic Syndrome with Depression and Anxiety in Patients Undergoing Weight Reduction Surgery

M. Stepanova, Z. Younossi, Yun Fang, 2010 .

Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.

L. Gerber, M. Stepanova, Z. Younossi, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Conformational analysis of the carboxy-terminal tails of human beta-tubulin isotypes.

J. Tuszynski, M. Stepanova, T. Luchko, 2008, Biophysical journal.

The Growing Economic and Clinical Burden of Nonalcoholic Steatohepatitis (NASH) in the United States.

M. Stepanova, L. Henry, Z. Younossi, 2022, Journal of clinical and experimental hepatology.

Adaptive computing for In Silico recognition of hormone response elements

Maria. Stepanova, M. Stepanova, 2008 .

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens

M. Stepanova, L. Henry, Z. Younossi, 2016, Medicine.

The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon‐ and ribavirin‐free regimens: a study of health‐related quality of life

M. Stepanova, S. Hunt, B. Lam, 2015, Alimentary pharmacology & therapeutics.

Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality

H. Makhlouf, Z. Goodman, M. Stepanova, 2011, Hepatology.

A comparative analysis of relative occurrence of transcription factor binding sites in vertebrate genomes and gene promoter areas

Maria Stepanova, Ancha V. Baranova, Tatiana Tiazhelova, 2005, Bioinform..

Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3

T. Asselah, M. Stepanova, L. Henry, 2018, Alimentary pharmacology & therapeutics.

Novel Point-of-Care Ultrasound (POCUS) Technique to Modernize the JVP Exam and Rule out Elevated Right Atrial Pressures

M. Stepanova, L. Istrail, L. Istrail, 2021, medRxiv.

Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C

M. Stepanova, G. Manyam, A. Birerdinc, 2010, Journal of viral hepatitis.

Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.

M. Stepanova, Haesuk Park, L. Henry, 2016, Gastroenterology.

Sofosbuvir and Velpatasvir Combination Improves Patient‐reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis

A. Mangia, M. Stepanova, S. Zeuzem, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results

M. Stepanova, F. Moiseenko, Ekaterina Ignatova, 2023, Clinical and Experimental Medicine.

Destabilizing polymorphism in cervid prion protein hydrophobic core determines prion conformation and conversion efficiency

M. Stepanova, H. Wille, L. Dorosh, 2017, PLoS pathogens.

T1011 Independent Predictors of Fibrosis in a Large Cohort of Patients with Non-Alcoholic Fatty Liver Disease

Z. Goodman, M. Stepanova, Z. Younossi, 2009 .

Predictors of chronic liver disease in individuals with human immunodeficiency virus infection.

M. Stepanova, Z. Younossi, M. Srishord, 2014, Annals of hepatology.

Understanding the dynamics of monomeric, dimeric, and tetrameric α‐synuclein structures in water

Jonathan Y. Mane, M. Stepanova, 2016, FEBS open bio.

Predictors of health‐related quality of life in patients with chronic liver disease

G. Marchesini, M. Stepanova, Z. Younossi, 2009, Alimentary pharmacology & therapeutics.

Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis.

V. Wong, Z. Goodman, M. Stepanova, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

A disease‐specific quality of life instrument for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis: CLDQ‐NAFLD

S. Hunt, M. Stepanova, L. Henry, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study

R. Jalan, D. Valla, M. Stepanova, 2018, Quality of Life Research.

Patient‐Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir

M. Stepanova, K. Kowdley, S. Zeuzem, 2017, Clinical Gastroenterology and Hepatology.

Patient‐reported outcomes in patients co‐infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL‐5 study

M. Stepanova, Z. Younossi, D. Wyles, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Vaccination against hepatitis A and B in patients with chronic liver disease and type 2 diabetes: has anything changed?

M. Stepanova, Z. Younossi, S. Clement, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B

M. Buti, M. Stepanova, Z. Younossi, 2021, JHEP reports : innovation in hepatology.

Recent trends in inpatient mortality and resource utilization for patients with stroke in the United States: 2005-2009.

M. Stepanova, Z. Younossi, C. Venkatesan, 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Direct and Indirect Economic Burden of Chronic Liver Disease in the United States

M. Stepanova, Z. Younossi, M. Afendy, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): A Population-based Study.

M. Stepanova, Z. Younossi, Maria Stepanova, 2013, Journal of clinical and experimental hepatology.

Adipokines and cytokines in non‐alcoholic fatty liver disease

A. Baranova, B. Ranard, Z. Goodman, 2007, Alimentary pharmacology & therapeutics.

Economic Burden and Patient-Reported Outcomes of Nonalcoholic Fatty Liver Disease.

M. Stepanova, L. Henry, Z. Younossi, 2023, Clinics in liver disease.

Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients

M. Stepanova, Z. Younossi, P. Golabi, 2019, Digestive Diseases and Sciences.

Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use

M. Stepanova, Z. Younossi, P. Golabi, 2019, Hepatology.

Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study

M. Stepanova, Z. Younossi, C. Venkatesan, 2014, BMJ Open.

Molecular Mechanisms in the Activation of Abscisic Acid Receptor PYR1

Maria Stepanova, Lyudmyla Dorosh, Olesya A. Kharenko, 2013, PLoS Comput. Biol..

P1324 LEDIPASVIR (LDV) AND SOFOSBUVIR (SOF) COMBINATION IMPROVES PATIENT-REPORTED OUTCOMES (PRO) DURING TREATMENT OF CHRONIC HEPATITIS C (CH-C) PATIENTS: RESULTS FROM THE ION-1 CLINICAL TRIAL

P. Marcellin, M. Stepanova, Z. Younossi, 2014 .

Superiority of Interferon-Free Regimens for Chronic Hepatitis C

S. Hunt, M. Stepanova, S. Zeuzem, 2017, Medicine.

Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

L. Gerber, M. Stepanova, L. Henry, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States

S. Saab, M. Stepanova, Z. Younossi, 2017, Clinical Diabetes.

Economic Burden of Hepatitis C Infection.

M. Stepanova, Z. Younossi, 2017, Clinics in liver disease.

French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes.

V. de Lédinghen, T. Asselah, M. Stepanova, 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection

L. Gerber, M. Stepanova, Z. Younossi, 2023, International journal of general medicine.

Editorial: the association of hepatitis C virus infection and post‐liver transplant diabetes – authors’ reply

M. Stepanova, Z. Younossi, 2015, Alimentary pharmacology & therapeutics.

The association of hepatitis C virus infection and post‐liver transplant diabetes: data from 17 000 HCV‐infected transplant recipients

S. Saab, M. Stepanova, L. Henry, 2015, Alimentary pharmacology & therapeutics.

Hepatic Fat Reduction Due to Resmetirom in Patients with Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.

M. Stepanova, Z. Younossi, R. Taub, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis

A. Baranova, Z. Goodman, M. Stepanova, 2011, Obesity surgery.

Hepatic Gene Expression of Caucasian and African-American Patients with Obesity-Related Non-Alcoholic Fatty Liver Disease

A. Baranova, Z. Goodman, M. Stepanova, 2010, Obesity surgery.

Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong

V. Wong, J. Fung, M. Stepanova, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life.

A. Mangia, K. Reddy, M. Stepanova, 2019, The American journal of gastroenterology.

Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection

L. Gerber, M. Stepanova, L. Henry, 2021, Hepatology communications.

Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

H. Makhlouf, Z. Goodman, M. Stepanova, 2013, Digestive Diseases and Sciences.

Dynamics of essential collective motions in proteins: theory.

M. Stepanova, Maria Stepanova, 2007, Physical review. E, Statistical, nonlinear, and soft matter physics.

Outcomes trends for acute myocardial infarction, congestive heart failure, and pneumonia, 2005-2009.

M. Stepanova, L. Henry, Z. Younossi, 2016, American Journal of Managed Care.

Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study

M. Stepanova, Z. Younossi, Nila Rafiq, 2010, Gut.

Corrigendum to "Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study" [J Hepatol 67 (2017) 940-949].

R. Jalan, D. Valla, M. Stepanova, 2018, Journal of Hepatology.

The combination of the enhanced liver fibrosis and FIB‐4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease

Z. Goodman, M. Stepanova, Z. Younossi, 2023, Alimentary pharmacology & therapeutics.

Structural domains and main-chain flexibility in prion proteins.

D. Wishart, M. Stepanova, M. Berjanskii, 2009, Biochemistry.

Aggregation of Aβ40/42 chains in the presence of cyclic neuropeptides investigated by molecular dynamics simulations

Min Wu, M. Stepanova, H. Wille, 2021, PLoS Comput. Biol..

Interaction of Aβ1-42 chains and fibrillary seeds studied by all-atom molecular dynamics simulations

M. Stepanova, L. Dorosh, Min Wu, 2020, Comput. Math. Methods.

Understanding interactions of functionalized nanoparticles with proteins: a case study on lactate dehydrogenase.

Oliver Stueker, M. Stepanova, G. Goss, 2014, Small.

Conformational modes in biomolecules: dynamics and approximate invariance.

M. Stepanova, A. Potapov, 2012, Physical review. E, Statistical, nonlinear, and soft matter physics.

Identification of dynamic structural domains in proteins, analysis of local bond flexibility and application for interpretation of NMR experiments

Maria Stepanova, M. Stepanova, 2009 .

Associations of chronic hepatitis C with metabolic and cardiac outcomes

M. Stepanova, Z. Younossi, E. Elsheikh, 2013, Alimentary pharmacology & therapeutics.

Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity

M. Stepanova, Z. Younossi, Y. Younossi, 2012, Journal of viral hepatitis.

Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease

M. Stepanova, Z. Younossi, M. Sayiner, 2016, BMJ open gastroenterology.

Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV).

M. Stepanova, Z. Younossi, A. Racila, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Expediting Treatment of Trauma Patients in the Emergency Department: Rapid Trauma Evaluation (RTE).

J. Howell, M. Stepanova, Anna B. Newcomb, 2023, The Journal of emergency medicine.

Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO

M. Stepanova, K. Kowdley, W. Lenderking, 2018, Hepatology.

Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes

M. Stepanova, H. Janssen, Z. Younossi, 2018 .

Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry.

M. Stepanova, Y. Eguchi, A. Duseja, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Association of Serum Adipocytokines with Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C

A. Baranova, M. Stepanova, Z. Younossi, 2010, Digestion.

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis

Z. Goodman, M. Stepanova, Z. Younossi, 2018, Medicine.

Hepatitis C Virus–Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens

M. Stepanova, Z. Younossi, J. Doyle, 2018, The Journal of infectious diseases.

Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study

L. Gerber, M. Stepanova, Z. Younossi, 2019, Journal of Neuroimmunology.

Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes

T. Asselah, M. Stepanova, L. Henry, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™

M. Buti, S. Hamid, M. Stepanova, 2023, Journal of viral hepatitis.

The impact of viral hepatitis‐related hepatocellular carcinoma to post‐transplant outcomes

S. Saab, M. Stepanova, L. Henry, 2016, Journal of viral hepatitis.

In silico modelling of hormone response elements

Feng Lin, Maria Stepanova, Valerie C.-L. Lin, 2006, BMC Bioinformatics.

The portrait of an adult liver transplant recipient in the United States from 1987 to 2013.

S. Saab, M. Stepanova, Z. Younossi, 2014, JAMA internal medicine.

The Impact of NASH to Liver Transplantations with Hepatocellular Carcinoma in the United States.

M. Stepanova, Z. Younossi, Y. Younossi, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

J. Kao, M. Stepanova, L. Henry, 2017 .

Outcomes of hospitalized patients with COVID-19 during the course of the pandemic in a fully integrated health system

L. Gerber, M. Stepanova, L. Henry, 2022, PloS one.

Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC

M. Stepanova, Z. Younossi, A. Racila, 2023, Hepatology communications.

Long-Term Patient Centered Outcomes in Cirrhotic Patients with Chronic Hepatitis C After Achieving Sustained Virologic Response.

M. Manns, M. Buti, A. Chokkalingam, 2021, Clinical Gastroenterology and Hepatology.

Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib

Z. Goodman, M. Stepanova, Z. Younossi, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Viral eradication is required for sustained improvement of patient‐reported outcomes in patients with hepatitis C

M. Manns, E. Schiff, M. Stepanova, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Association of work productivity with clinical and patient‐reported factors in patients infected with hepatitis C virus

M. Stepanova, L. Henry, S. Hunt, 2016, Journal of viral hepatitis.

Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir

M. Stepanova, M. Choi, L. Henry, 2016, Medicine.

Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity.

M. Stepanova, Z. Younossi, A. Weinstein, 2016, Psychosomatics.

Long-Term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients with Chronic HCV Infection.

K. Reddy, M. Stepanova, Z. Younossi, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Liver Transplant Center Size and the Impact on Clinical Outcomes and Resource Utilization

M. Stepanova, Z. Younossi, S. Alqahtani, 2021, Transplantation.

Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening of Patient-Reported Outcomes.

M. Stepanova, S. Zeuzem, S. Pol, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tiger HRE Finder - A Tool for Identification of Hormone Receptor Binding Sites in Query Sequences

Lin Feng, Maria Stepanova, Valerie C.-L. Lin, 2006, First International Multi-Symposiums on Computer and Computational Sciences (IMSCCS'06).

Outcomes of liver transplantation by insurance types in the United States.

M. Stepanova, Z. Younossi, C. Venkatesan, 2020, The American journal of managed care.

Severe impairment of patient‐reported outcomes in patients with chronic hepatitis C virus infection seen in real‐world practices across the world: Data from the global liver registry

M. Buti, S. Hamid, M. Stepanova, 2022, Journal of viral hepatitis.

A Hopfield Neural Classifier and Its FPGA Implementation for Identification of Symmetrically Structured DNA Motifs

Feng Lin, Maria Stepanova, Valerie C.-L. Lin, 2007, J. VLSI Signal Process..

An exploratory study examining how nano-liquid chromatography–mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease

E. Petricoin, Z. Goodman, M. Stepanova, 2018, BMC Medicine.

Anthropometric and Clinical Factors Associated with Mortality in Subjects with Nonalcoholic Fatty Liver Disease

L. Gerber, M. Stepanova, Z. Younossi, 2013, Digestive Diseases and Sciences.

The Economic and Clinical Burden of Non-Alcoholic Fatty Liver Disease in the United States

M. Stepanova, L. Henry, Z. Younossi, 2016 .

Improvement of hepatic fibrosis in patients with non-alcoholic steatohepatitis treated with selonsertib is associated with improvement of patient-reported outcomes (PROS)

Z. Goodman, M. Stepanova, Z. Younossi, 2017 .

Non-alcoholic steatofibrosis is independently associated with both overall mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)

Z. Goodman, M. Stepanova, Z. Younossi, 2017 .

Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes.

M. Stepanova, H. Janssen, Z. Younossi, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Regular Exercise Is Associated With Low Fatigue Levels and Good Functional Outcomes After COVID-19

L. Gerber, M. Stepanova, Z. Younossi, 2023, American journal of physical medicine & rehabilitation.

How long is too long: A retrospective study evaluating the impact of the duration of noninvasive oxygenation support strategies (high flow nasal cannula & BiPAP) on mortality in invasive mechanically ventilated patients with COVID-19

M. Stepanova, M. Desai, B. Lam, 2023, PloS one.

Stigma in NAFLD and NASH: a global survey of patients and providers

V. Wong, K. Cusi, T. Kawaguchi, 2023, Journal of Hepatology.

Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials

M. Stepanova, M. Mizokami, M. Omata, 2017, Health and Quality of Life Outcomes.

A new comorbidity model for predicting mortality in patients with cirrhosis: does it work?

M. Stepanova, L. Henry, Z. Younossi, 2014, Gastroenterology.

Letter: new treatments for hepatitis C have implications for quality of life in people who inject drug – authors' reply

M. Stepanova, Z. Younossi, 2016, Alimentary pharmacology & therapeutics.

Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example

E. Petricoin, A. Baranova, M. Stepanova, 2013, PloS one.

Letter: effects of hepatitis C infection on the post‐lung transplant mortality – authors’ reply

M. Stepanova, Z. Younossi, 2016, Alimentary pharmacology & therapeutics.

Associations of Obesity-Related Non-Alcoholic Fatty Liver Disease (NAFLD) and Autoimmune Diseases: A Secondary Data Analysis of the National Health and Nutrition Examination Survey (NHANES) 1999-2014

L. Gerber, M. Stepanova, Z. Younossi, 2017 .

The portrait of adult liver transplant recipients in the United States from 2002 to 2020

M. Stepanova, L. Henry, Z. Younossi, 2022, Journal of Hepatology.

Insurance status and treatment candidacy of hepatitis C patients: Analysis of population‐based data from the United States

H. El‐Serag, M. Stepanova, Z. Younossi, 2011, Hepatology.

Comparative analysis of essential collective dynamics and NMR-derived flexibility profiles in evolutionarily diverse prion proteins

D. Wishart, M. Stepanova, M. Berjanskii, 2011, Prion.

Methods and strategies for construction of a phylogeny-adaptive hormone response element consensus model

Lin Feng, Maria Stepanova, Jesslyn Saw, 2008, 2008 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology.

Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population

M. Stepanova, Z. Younossi, 2011, Hepatology.

Adipokines and cytokines in non‐alcoholic fatty liver disease

A. Baranova, Z. Goodman, M. Stepanova, 2007, Alimentary pharmacology & therapeutics.

Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

M. Stepanova, Z. Younossi, Yun Fang, 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The outcomes of adult liver transplants in the United States from 1987 to 2013

S. Saab, M. Stepanova, Z. Younossi, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity

M. Stepanova, Z. Younossi, B. Lam, 2012, Journal of Viral Hepatitis.

Severe, Persistent, Disruptive Fatigue Post-SARS-CoV-2 Disproportionately Affects Young Women

M. Stepanova, Z. Younossi, A. Weinstein, 2023, International journal of general medicine.